Kouji Itou

Dr. Kouji Itou


Research Focus & Metrics

Academic Career Length

31Years (1996-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2010 in Journal of Bioscience and Bioengineering
Verified
Journal Article
Closed access
KMKeiko Miyoshi
Keiko Miyoshi
DTDaisuke Tsuji
Daisuke Tsuji
KKKeiko Kudoh
Keiko Kudoh
Kazuhito SatomuraKazuhito Satomura
Kazuhito Satomura
TMTaro Muto
Taro Muto
TNTakafumi Noma
Takafumi Noma

1 June 2011 in Molecular Therapy
Verified
Journal Article
Open access
PDF file
KMKazuhiko Matsuoka
Kazuhiko Matsuoka
TTTomomi Tamura
Tomomi Tamura
DTDaisuke Tsuji
Daisuke Tsuji
YDYukie Dohzono
Yukie Dohzono
KKKeisuke Kitakaze
Keisuke Kitakaze
KIKouji Itou
Kouji Itou
To develop a novel enzyme replacement therapy for neurodegenerative Tay-Sachs disease (TSD) and Sandhoff disease (SD), which are caused by deficiency of β-hexosaminidase (Hex) A, we designed a genetically engineered HEXB encoding the chimeric human β-subunit containing partial amino acid sequence of the α-subunit by structure-based homology modeling. We succeeded in producing the modified HexB by a Chinese hamster ovary (CHO) cell line stably expressing the chimeric HEXB, which can degrade artificial anionic substrates and GM2 ganglioside in vitro, and also retain the wild-type (WT) HexB-like thermostability in the presence of plasma. The modified HexB was efficiently incorporated via cation-independent mannose 6-phosphate receptor into fibroblasts derived from Tay-Sachs patients, and reduced the GM2 ganglioside accumulated in the cultured cells. Furthermore, intracerebroventricular administration of the modified HexB to Sandhoff mode mice restored the Hex activity in the brains, and reduced the GM2 ganglioside storage in the parenchyma. These results suggest that the intracerebroventricular enzyme replacement therapy involving the modified HexB should be more effective for Tay-Sachs and Sandhoff than that utilizing the HexA, especially as a low-antigenic enzyme replacement therapy for Tay-Sachs patients who have endogenous WT HexB.

1 January 2002 in Journal of Human Genetics
Verified
Journal Article
Closed access
KIKouji Itou
Kouji Itou
YNYasunori Naganawa
Yasunori Naganawa
FMFumiko Matsuzawa
Fumiko Matsuzawa
SASeiichi Aikawa
Seiichi Aikawa
HDHirofumi Doi
Hirofumi Doi
HSHitoshi Sakuraba
Hitoshi Sakuraba

28 March 2016 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
KKKeisuke Kitakaze
Keisuke Kitakaze
YMYasumichi Mizutani
Yasumichi Mizutani
ESEiji Sugiyama
Eiji Sugiyama
CTChikako Tasaki
Chikako Tasaki
DTDaisuke Tsuji
Daisuke Tsuji
KIKouji Itou
Kouji Itou
GM2 gangliosidoses, including Tay-Sachs and Sandhoff diseases, are neurodegenerative lysosomal storage diseases that are caused by deficiency of β-hexosaminidase A, which comprises an αβ heterodimer. There are no effective treatments for these diseases; however, various strategies aimed at restoring β-hexosaminidase A have been explored. Here, we produced a modified human hexosaminidase subunit β (HexB), which we have termed mod2B, composed of homodimeric β subunits that contain amino acid sequences from the α subunit that confer GM2 ganglioside–degrading activity and protease resistance. We also developed fluorescent probes that allow visualization of endocytosis of mod2B via mannose 6-phosphate receptors and delivery of mod2B to lysosomes in GM2 gangliosidosis models. In addition, we applied imaging mass spectrometry to monitor efficacy of this approach in Sandhoff disease model mice. Following i.c.v. administration, mod2B was widely distributed and reduced accumulation of GM2, asialo-GM2, and bis(monoacylglycero)phosphate in brain regions including the hypothalamus, hippocampus, and cerebellum. Moreover, mod2B administration markedly improved motor dysfunction and a prolonged lifespan in Sandhoff disease mice. Together, the results of our study indicate that mod2B has potential for intracerebrospinal fluid enzyme replacement therapy and should be further explored as a gene therapy for GM2 gangliosidoses.

1 February 2009 in Biochemical and Biophysical Research Communications
Verified
Journal Article
Closed access
TITatsuo Ito
Tatsuo Ito
MAMakiko Azumano
Makiko Azumano
CUChisana Uwatoko
Chisana Uwatoko
KIKouji Itou
Kouji Itou
JKJun Kuwahara
Jun Kuwahara

1 December 2010 in Biochemical and Biophysical Research Communications
Verified
Journal Article
Closed access
TITatsuo Ito
Tatsuo Ito
HKHaruka Kitamura
Haruka Kitamura
CUChisana Uwatoko
Chisana Uwatoko
MAMakiko Azumano
Makiko Azumano
KIKouji Itou
Kouji Itou
JKJun Kuwahara
Jun Kuwahara